Beispiel: Heart Attack

Klinische Studien gesponsert von ALZA

Insgesamt 43 ergebnisse

NCT00003827

Unbekannter Status

Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome

Bedingungen: Leukemia; Myelodysplastic Syndromes
NCT01230762

Abgeschlossen

An Open-Label Study of the Long-Term Safety of Dapoxetine HCl in the Treatment of Rapid Ejaculation

Bedingungen: Ejaculation; Erectile Dysfunction; Sexual Dysfunction
NCT00990418

Abgeschlossen

Bioequivalence Between Integrated E-TRANS (Fentanyl) System and Separated (Two-Part) E-TRANS (Fentanyl) System

Bedingungen: Pain, Postoperative
NCT00177281

Abgeschlossen

Safety Study of S-CKD602 in Patients With Advanced Malignancies

Bedingungen: Cancer
NCT00003225

Abgeschlossen

Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer

Bedingungen: Colorectal Cancer
NCT00714584

Abgeschlossen

Pharmacokinetics of Naltrexone Following Intravenous and Oral Routes of Administration in Healthy Volunteers

Bedingungen: Biological Availability
NCT00714558

Abgeschlossen

Pharmacokinetics of Fentanyl Following Intravenous and Oral Routes of Administration in Healthy Volunteers

Bedingungen: Biological Availability
NCT00666393

Zurückgezogen

An Evaluation of Safety of the Fentanyl Transdermal System for Management of Acute Post-Operative Pain in Pediatric Patients

Bedingungen: Pain, Postoperative; Pediatrics
NCT00665522

Beendet

A Prospective Safety Surveillance Study of Fentanyl Iontophoretic Transdermal System (40 Mcg)

Bedingungen: Pain
NCT00650182

Abgeschlossen

A Study to Evaluate the Safety of D-TRANS Fentanyl With Naltrexone in Adult Patients With Chronic Pain and Who Are Opioid Tolerant

Bedingungen: Chronic Pain
NCT00424931

Abgeschlossen

A Safety and Effectiveness Study of a Single Dose of JNJ-17216498 in Patients With Narcolepsy

Bedingungen: Narcolepsy
NCT00411307

Abgeschlossen

A Randomized, Open-Label, Single-Dose, Small Study to Evaluate the Safety and Effectiveness of Hydromorphone in Patients With Short Term, Moderate to Severe Postoperative Pain

Bedingungen: Pain, Postoperative; Orthopedic Procedures; Analgesia
NCT00411268

Abgeschlossen

Safety, Effectiveness, and Impact on Quality of Life on Long-Term Administration of OROS Hydromorphone Slow-Release in Patients With Chronic Low Back Pain

Bedingungen: Low Back Pain
NCT00411164

Abgeschlossen

A Study to Evaluate the Effectiveness and Safety of Slow Release Hydromorphone HCL for Treatment of Patients With Osteoarthritis

Bedingungen: Osteoarthritis, Hip; Osteoarthritis, Knee
NCT00411034

Abgeschlossen

A Repeated-Dose Evaluation of Use of a Pain Relieving Drug and Safety of OROS Hydromorphone HCI in Patients With Chronic Cancer Pain

Bedingungen: Analgesics, Opioid; Pain
NCT00410943

Abgeschlossen

Study of the Effectiveness and Tolerability of OROS Hydromorphone HCI SR(Slow-release) Tablets and Immediate-Release Hydromorphone Tablets in Patients With Chronic Pain

Bedingungen: Pain
NCT00410878

Abgeschlossen

A Repeated Dose Study of the Metabolism and Action Evaluation of OROS Hydromorphone HCI (Slow Release) Tablets in Patients With Chronic Pain

Bedingungen: Pain; Analgesics, Opioid
NCT00410787

Abgeschlossen

Safety and Tolerability of Long-term Administration of OROS Hydromorphone HCI (Slow Release) in Cancer Pain

Bedingungen: Analgesics, Opioid; Pain
NCT00410748

Abgeschlossen

Safety and Tolerability of Long-Term Administration of Hydromorphone HCI CR (Controlled Release)

Bedingungen: Pain; Analgesics, Opioid
NCT00410644

Abgeschlossen

A Repeated-Dose Evaluation of a Pain Relieving Drug Use and Safety of OROS Hydromorphone HCI in Patients With Chronic Non-Malignant Pain

Bedingungen: Pain; Analgesics; Opioid
NCT00410540

Abgeschlossen

A Study of OROS Hydromorphone HCL vs Morphine in Cancer Pain Patients.

Bedingungen: Pain; Analgesics, Opioid
NCT00399295

Abgeschlossen

An Open-Label Evaluation of the Independent Effects of Coadministration of a High-Fat Meal and Naltrexone Blockade on the Pharmacokinetic Profile of Dilaudid OROS (Hydromorphone HCI) 16mg

Bedingungen: Analgesia
NCT00399048

Abgeschlossen

An Effectiveness, Safety and Quality of Life Measures With Hydromorphone HCL, Dilaudid CR (Controlled Release)

Bedingungen: Osteoarthritis, Knee; Osteoarthritis, Hip
NCT00398957

Abgeschlossen

An Open-Label Evaluation of the Dose Proportionality of OROS� Hydromorphone HCL Tablets 8mg, 16mg, 32mg, 64mg

Bedingungen: Analgesia
NCT00398788

Abgeschlossen

A Study on Efficacy (Effectiveness), Safety, and Impact on Quality of Life Measures of Dilaudid CR (Controlled Release);, Hydromorphone HCl in Patients With Chronic Low Back Pain

Bedingungen: Low Back Pain